Fibroid Clinical Trial - Ulipristal Use in Chinese Population

Status Terminated

Clinical Trial Summary

Uterine leiomyomas is the commonest benign tumour of the female genital tract. It lead to menorrhagia, anaemia, pain and pressure symptoms. Due to the enlarged uterus, the use of minimal invasive surgery is limited. There is also increase risk of intraoperative blood transfusion. Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). Preoperative use of Ulipristal for 12 weeks has been shown to decrease uterine bleeding, fibroid volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy, especially in Chinese population. The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid.

Clinical Trial Description

Uterine leiomyomas is the commonest benign tumour of the female genital tract. It is often asymptomatic, but can also lead to anaemia, pain and pressure symptoms. It is the commonest indication for hysterectomy, especially abdominal hysterectomy. Currently, the use of hormonal treatment is associated with side effects including gastrointestinal upset, bloating, weight gain and thromboembolic risks. The main stay for treatment relies on surgery.

Furthermore, the use of minimal invasive surgeries is limited by the size of the fibroids. Preoperative use of Gonadotrophic Releasing Hormone analogues (GnRHa) is effective in shrinkage of the uterine leiomyomas and reduction of uterine bleeding. However, postmenopausal symptoms including hot flushes, vaginal dryness are profound.

Ulipristal acetate (UPA), previously named CDB-2914, is a selective progesterone-receptor modulator (SPRM). It binds to the progesterone receptors with high affinity. It inhibits follicular development and ovulation, while it has no significant effects on estradiol levels and antiglucocorticoid activity. Preoperative use of Ulipristal for symptomatic uterine fibroids has been investigated in randomized controlled study with improvement in terms of uterine bleeding, fibroids volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy. Also there is lack of evidence in Chinese population.

The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02825719
Study type	Interventional
Source	Queen Mary Hospital, Hong Kong
Contact
Status	Terminated
Phase	Phase 4
Start date	December 2, 2015
Completion date	March 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00891657` - Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy	N/A
Active, not recruiting	`NCT03323905` - Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas	N/A
Recruiting	`NCT06135870` - Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
Recruiting	`NCT03143114` - Effect of Myomectomy for Intramural Myoma on Fertility Outcomes in Infertile Women	N/A
Not yet recruiting	`NCT06143631` - Prescription of Letrozole for Uterine Myoma	Phase 4
Recruiting	`NCT03784976` - Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis	N/A
Completed	`NCT02166411` - Laparoscopic Myomectomy Using Barbed or Conventional Sutures	Phase 2
Completed	`NCT04736095` - 3 Dimensional Ultrasound in Comparison to Hysteroscopy in Myomas
Recruiting	`NCT02357563` - Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation	Phase 4
Recruiting	`NCT02361879` - Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma	Phase 4
Recruiting	`NCT02361905` - Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas	Phase 4
Completed	`NCT00427544` - Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential	Phase 1
Enrolling by invitation	`NCT03937401` - Oxytocin in MRI-HIFU	Phase 4
Completed	`NCT00746031` - Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids	Phase 4
Recruiting	`NCT00323999` - Hysteroscopic Monopolar and Bipolar Resection	N/A
Not yet recruiting	`NCT03122782` - Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.